3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
Patent 5703208 Issued on December 30, 1997. Estimated Expiration Date: 
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Inventors
ApplicationNo. 484720 filed on 06/07/1995US Classes:530/331, Tripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc.540/463, Nitrogen or additional chalcogen attached directly to the hetero ring by nonionic bonding540/487, Silicon or phosphorus attached directly or indirectly to the hetero ring by nonionic bonding540/524, Additional hetero ring containing540/527, Nitrogen bonded directly to the hetero ring546/24, Chalcogen bonded directly to ring carbon of the six-membered hetero ring546/192, Additional ring containing546/243, At 2-position548/413, Phosphorus attached indirectly to the five-membered hetero ring by nonionic bonding548/517, Additional hetero ring, which is attached directly or indirectly to the five-membered hetero ring by nonionic bonding548/547Chalcogen attached indirectly to the five-membered hetero ring by acyclic nonionic bondingExaminersPrimary: Johnson, Jerry D.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 038/06A61K 038/00 C07D 225/02 C07F 009/06 AbstractThe present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Field of SearchTripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc.Nitrogen or additional chalcogen attached directly to the hetero ring by nonionic bonding Silicon or phosphorus attached directly or indirectly to the hetero ring by nonionic bonding Additional hetero ring containing Nitrogen bonded directly to the hetero ring Chalcogen bonded directly to ring carbon of the six-membered hetero ring Additional ring containing At 2-position Phosphorus attached indirectly to the five-membered hetero ring by nonionic bonding Additional hetero ring, which is attached directly or indirectly to the five-membered hetero ring by nonionic bonding Chalcogen attached indirectly to the five-membered hetero ring by acyclic nonionic bonding 3 or 4 peptide repeating units in known peptide chain 2 peptide repeating units in known peptide chain Guanidine containing |
| ||||||||||||||
